Document details
Document title
BISPHOSPHONATE TREATMENT IN POLYOSTOTIC FIBROUS DYSPLASIA OF THE CRANIUM: CASE REPORT AND LITERATURE REVIEW
Author(s)
MANSOORI Lela S. ; CATEL Colin P. ; ROTHMAN Micol S.
Abstract
Objective: To report the case of a patient with polyostotic fibrous dysplasia of the cranium who showed dramatic improvement after treatment with intravenous zoledronic acid. Methods: We present the clinical findings, laboratory test results, surgical pathology report, and imaging studies of a man with extensive fibrous dysplasia of the cranium and review the literature regarding the use of bisphosphonates in patients with this debilitating skeletal disorder. Results: A 32-year-old man presented with chronic occipital headache, and computed tomography of the head revealed extensive bony lesions of the middle and posterior cranial fossa. Bone biopsy confirmed the diagnosis of fibrous dysplasia. Laboratory blood test results revealed elevated serum alkaline phosphatase (140 U/L [reference range, 39-117 U/L]) and elevated serum bone-specific alkaline phosphatase (30.6 μg/L [reference range, 6-20 μg/L]). The patient was treated with intravenous pamidronate without improvement, and therapy was switched to zoledronic acid, which resulted in rapid resolution of headache symptoms, decrease in bone-specific alkaline phosphatase levels to 24.9 μg/L, and dramatic radiologic improvement on repeated computed tomography of the head. Conclusions: The treatment options for fibrous dysplasia of the cranium have been limited to conservative follow-up or surgery, and the use of zoledronic acid in this condition has not been previously reported. Intravenous bisphosphonate therapy is suggested
Publisher
The College and the Association
Identifier
ISSN : 1530-891X
Source
Endocrine practice Y. 2010, vol. 16, No. 5, pages 851-854 [4 pages]
Language
English
This document can be reproduced free for members of the CNRS community.
For members of communities outside the CNRS, the paid reproduction of this document is subject to the authorization of the Centre Français d’Exploitation du Droit de Copie (Copyright authorities).

To use our services (strictly reserved for members of the CNRS (National Center for Scientific Research), French Higher Education and Research and public sector communities in France and other countries):